CANC

Tema Oncology ETF

41.83

Jul 02 • 04:00PM ET +1.02 (2.50%)

Financial Exchange Traded Fund USA NASD

Category	Global or ExUS Equities - Industry Sector
Sponsor	Tema
Fund Family
Index	-
Index Weighting
Active/Passive
Dividend TTM	0.02 (0.05%)
Dividend Ex-Date	Dec 10, 2025
Dividend Gr. 3/5Y	- -
Expense	0.75%
Inverse/Leveraged
IPO	Aug 16, 2023

Asset Type	Equities (Stocks)
ETF Type
Bond Type
Average Maturity
Commodity Type
Quant Type
ESG Type
Dividend Type
Structure Type
Growth/Value
Market Cap
Option/Short	No / Yes

Tags	Global
Tags	equity
Tags	healthcare
Tags	-
Tags	-
Tags	-
Tags	-
Sector/Theme
Region
SMA20	8.91%
SMA50	10.24%
SMA200	18.81%

Return% 1Y	65.15%
Return% 3Y	-
Return% 5Y	-
Return% 10Y
Return% SI
Flows% 1M	-0.41%
Flows% 3M	0.25%
Flows% YTD	32.85%
Flows% 1Y
Flows% 3Y
Flows% 5Y
Trades

Total Holdings	58
AUM	188.30M
NAV/sh
52W High	41.88 -0.11%
52W Low	23.49 78.07%
Volatility	2.07% 2.16%
ATR (14)	0.90
RSI (14)	73.03
Beta	0.69
Rel Volume	0.60
Avg Volume	31.17K
Volume	18,638

Perf Week	5.90%
Perf Month	15.02%
Perf Quarter	12.68%
Perf Half Y	20.53%
Perf YTD	20.47%
Perf Year	65.79%
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Prev Close	40.81
Price	41.83
Change	2.50%

Jan-09-26 10:00AM	Here's Why Biotech ETFs Are Rallying Hard (Zacks)
Dec-02-25 06:00AM	Temas Oncology ETF (CANC) Surpasses $100m in Assets Amidst Strong 2025 Performance (Business Wire)
Nov-26-25 10:00AM	Be Thankful to These ETFs This Year (Zacks)
Nov-21-25 08:00AM	Inside the Recent Strength in Biotech ETFs (Zacks)
Oct-20-25 06:00AM	Biotech ETFs Bounce Back in 2025: Here's Why (Zacks)

Tema Oncology ETF seeks to provide long-term growth. Under normal circumstances, the fund seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from oncology. The fund is non-diversified.

open in yahoo | open in marketwatch | open in google

$100 Off Your First Year Get Elite For Just $199.50

CANC

Tema Oncology ETF

Upgrade your Finviz experience